News

Stay Up-To-Date on NEXT Oncology

NEXT Oncology’s Ildefonso Ismael Rodriguez Rivera, MD Leads Phase 1 Trial of Precemtabart-Tocentecan in Metastatic Colorectal Cancer

Phase 1 trial findings published in Nature Medicine show promise for a new approach to targeting colorectal cancer and other tumors expressing CEACAM5. NEXT Oncology’s Dr. Ildefonso Ismael Rodriguez Rivera, ...

NEXT Oncology Expands to Brazil in Strategic Partnership with Oncologia D’Or and IDOR

With continued global expansion, NEXT Oncology is one of the world’s largest Phase 1 Cancer Trial organizations. (SAN ANTONIO, TX) July 29, 2025 –– NEXT Oncology has expanded its services ...

Dr. David Sommerhalder Named 2025 San Antonio Business Journal Health Care Hero

We are so proud that Dr. David Sommerhalder has been selected as a 2025 Health Care Hero in the Medical Research Category by the San Antonio Business Journal. Read more ...

Alterome Doses First Patient in Phase 1 Study of ALTA3263, a Novel Pan-KRAS Dual ON/OFF Inhibitor, in Advanced Solid Tumors

ALTA3263 is a potential best-in-class KRAS-selective small molecule inhibitor that potently targets >90% of KRAS mutations. Read More

Iambic Completes Dose Escalation in Ongoing Phase 1/1B Study of Lead Program IAM1363, a Small Molecule Inhibitor of Wild-Type and Oncogenic HER2 Mutant Proteins

Designed with Iambic’s AI-Drug Discovery platform, IAM1363 is highly differentiated by its target selectivity, brain-penetrance, pan-mutant activity, and tumor enrichment. Read More

Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-1418, a Potential Best-in-Class, Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate

Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced initiation of a Phase 1/2 clinical study of its potential best-in-class EGFR/HER3 bispecific antibody-drug conjugate, AVZO-1418, ...

NEXT Oncology Names Dr. Alex Spira Chief Scientific Officer

Dr. Spira to lead scientific and research strategy, advancing Phase 1 oncology trials. SAN ANTONIO, TX – May 20, 2025 – NEXT Oncology, one of the world’s largest Phase 1 ...

Crown Bioscience and NEXT Oncology Cement Partnership Extension

Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and part of JSR Life Sciences and Japan-based JSR Corporation, is pleased to announce the extension of ...

Tagworks Pharmaceuticals Announces FDA Clearance of IND Application and Initiation of Phase 1 Clinical Trial for TGW101 and Appoints Keith Orford, MD, PhD, as Chief Medical Officer

Tagworks Pharmaceuticals BV (“Tagworks”), a clinical-stage precision oncology company using its proprietary Click-to-Release treatment platform to develop a new standard of care for patients suffering from solid tumors, today announced ...

Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors

Initial clinical activity in a PD-(L)1 resistant population, with an ORR almost three times higher than historical PD-(L)1 rechallenge response rates, with data still maturing. Read More